Literature DB >> 15866444

A process for the separation of 177Lu from neutron irradiated 176Yb targets.

E P Horwitz1, D R McAlister, A H Bond, R E Barrans, J M Williamson.   

Abstract

A conceptual flowsheet has been developed for the separation of (177)Lu from a 300 mg neutron irradiated (176)Yb enriched target. The key component of the process is an extraction chromatographic (EXC) resin containing 2-ethylhexyl 2-ethylhexylphosphonic acid (HEH[EHP]) sorbed onto a 25-53 microm Amberchrom CG-71 substrate. The process is divided into three sections: (1) front-end target removal system, (2) primary separation system and (3) secondary separation system. Each section involves the separation of Yb and Lu using the HEH[EHP] resin followed by concentration and acid adjustment of the Lu-rich eluate using an EXC material containing a diglycolamide extractant. The use of the diglycolamide EXC material is a significant feature of the flowsheet, allowing one to avoid lengthy evaporations and acidity adjustments between successive HEH[EHP] column runs while removing adventitious impurities from the (177)Lu. The overall recovery of (177)Lu is estimated at 73% with an overall decontamination factor from Yb of 10(6). The overall processing time can be as short as 4h.

Entities:  

Year:  2005        PMID: 15866444     DOI: 10.1016/j.apradiso.2005.02.005

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  8 in total

Review 1.  Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Authors:  Ashutosh Dash; Maroor Raghavan Ambikalmajan Pillai; Furn F Knapp
Journal:  Nucl Med Mol Imaging       Date:  2015-02-17

Review 2.  A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

Authors:  Rubel Chakravarty; Sudipta Chakraborty
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

3.  Stability of 47Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Authors:  Magdalena Połosak; Agata Piotrowska; Seweryn Krajewski; Aleksander Bilewicz
Journal:  J Radioanal Nucl Chem       Date:  2012-09-13       Impact factor: 1.371

Review 4.  The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Authors:  Evan D Read; Peter Eu; Peter J Little; Terrence J Piva
Journal:  Target Oncol       Date:  2014-05-29       Impact factor: 4.493

5.  Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.

Authors:  Nafise Salek; Mojtaba Shamsaei; Mohammad Ghannadi Maragheh; Simindokht Shirvani Arani; Ali Bahrami Samani
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

6.  Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy.

Authors:  Michiel Van de Voorde; Charlotte Duchemin; Reinhard Heinke; Laura Lambert; Eric Chevallay; Thomas Schneider; Miranda Van Stenis; Thomas Elias Cocolios; Thomas Cardinaels; Bernard Ponsard; Maarten Ooms; Thierry Stora; Andrew R Burgoyne
Journal:  Front Med (Lausanne)       Date:  2021-07-19

7.  Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

Authors:  R Bhardwaj; A van der Meer; S K Das; M de Bruin; J Gascon; H T Wolterbeek; A G Denkova; P Serra-Crespo
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

8.  A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy.

Authors:  Isidro Da Silva; Taylor R Johnson; Jason C Mixdorf; Eduardo Aluicio-Sarduy; Todd E Barnhart; R Jerome Nickles; Jonathan W Engle; Paul A Ellison
Journal:  Molecules       Date:  2021-12-11       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.